Wolomin

Researchers are evaluating the long-term safety and tolerability of dazodalibep in adults with Sjögren's Syndrome. This phase 3 open-label extension study focuses on participants who have previously received dazodalibep or placebo in earlier phase 3 trials and completed those studies through Week 48. Participants will receive dazodalibep intravenously during this long-term extension study. The first dose is administered around Week 48 (+28 days) following the prior phase 3 studies. The study monitors safety and tolerability over an extended period to assess treatment-emergent adverse events up to 152 weeks. During the study, participants will undergo regular evaluations to monitor their health and any side effects. Researchers will collect data on adverse events that emerge during treatment. The overall goal is to gather long-term safety information to better understand how participants tolerate dazodalibep when used over an extended time frame.

Researchers are evaluating the effects of osteopathic techniques on the autonomic nervous system (ANS) activity in healthy individuals. This study focuses on two specific methods: the fourth ventricle compression (CV4) technique, which targets brain and cranial nerve function, and rib raising (RR), which aims to reduce rib restriction and conditions linked to sympathetic nervous system overactivity. About 109 healthy participants will be involved to assess changes in heart rate variability (HRV), an indicator of ANS function. Participants will be randomly assigned to one of three groups. The first group will receive three 30-minute sessions combining CV4 and RR once a week for three weeks. The second group will undergo three 30-minute sessions of only the CV4 technique on the same weekly schedule. The third group will receive a sham procedure using an ultrasound transducer, mimicking therapy but without actual treatment, also over three weekly 30-minute sessions. These interventions aim to compare the effects of active osteopathic techniques versus placebo on ANS activity. Throughout the study, HRV measurements will be taken at three different times: before any intervention (baseline), immediately after the third session (post-intervention), and one month after the last session (follow-up). The evaluations will be done in a seated position for five minutes using specialized devices that monitor heart rate variability and related physiological signals. Researchers will analyze these data to understand how these osteopathic techniques influence ANS function over time.

Researchers are evaluating the safety, tolerability, and effectiveness of IMVT-1402 in adults with moderate to severe systemic primary Sjogren's disease. This Phase 2b study compares IMVT-1402 to a placebo using a double-blind, randomized, placebo-controlled design. The main goal is to see how the treatment affects disease activity scores over 24 weeks, with participation lasting up to 105 weeks. Participants receive either IMVT-1402 or placebo through weekly subcutaneous injections. The study carefully monitors changes in disease activity, focusing on a clinical score called clinESSDAI. The trial includes a long observation period to track both the treatment's effects and safety over time. During the study, participants undergo evaluations at the start and at week 24 to measure changes in their disease activity. Researchers will also monitor safety and tolerability throughout the entire study period. Participants are assessed for antibody status, salivary flow, and systemic disease activity to understand the impact of the treatment fully.

Researchers are evaluating the effectiveness and safety of sonelokimab compared with placebo in adults with active psoriatic arthritis who have not responded well or could not tolerate anti-tumor necrosis factor alpha (TNFb1) therapy. This Phase 3, randomized, double-blind study also includes risankizumab as an active reference treatment to better understand the benefits and risks of sonelokimab for this condition. Participants will be randomly assigned to one of four groups receiving either sonelokimab at doses of 60 mg or 120 mg, placebo, or risankizumab. The treatments are given by injection under the skin. The study is conducted across multiple centers and compares the response rates after 16 weeks of treatment to evaluate improvement in psoriatic arthritis symptoms. During the trial, participants will undergo joint assessments, blood tests for specific antibodies, and evaluations of skin psoriasis. Researchers will monitor how many participants achieve at least a 50% improvement in arthritis criteria compared to placebo. Safety and side effects will be closely observed throughout the study. The total time involved includes screening, treatment, and follow-up visits to ensure thorough evaluation of both effectiveness and safety.

This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months. Participants are in the study for up to 1 year and 8 months. During this time, participants visit the study site up to 10 times and get about 13 phone calls from the site staff. Participants regularly complete a diary on a smartphone about their bronchiectasis symptoms and study doctors regularly check for any changes. The study doctors document when participants experience flare-ups. The number of flare-ups is compared between the participants who receive BI 1291583 and those who receive the placebo. The study doctors also regularly check participants' health and take note of any unwanted effects.